New and emerging drug therapies for the management of acute heart failure.
In recent times, there have been many developments in therapies for acute heart failure, in contrast to the preceding 20 years. These have been mainly fueled by new and expanding knowledge about the pathophysiology of heart failure, which has allowed for insight into potential therapeutic strategies. This review will examine the key emerging therapies for acute heart failure, in light of available pathophysiological and clinical evidence.
Krum
H
H
Department of Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria, Australia. henry.krum@med.monash.edu.au
Liew
D
D
D065092:Antidiuretic Hormone Receptor Antagonists; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006835:Hydrazones / Q000627:therapeutic use; D045283:Natriuretic Agents / Q000627:therapeutic use; D020097:Natriuretic Peptide, Brain / Q000627:therapeutic use; D011724:Pyridazines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D000077464:Simendan; D013777:Tetrazoles / Q000627:therapeutic use; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use; D014667:Vasopressins / Q000037:antagonists & inhibitors
D065092:Antidiuretic Hormone Receptor Antagonists; D006835:Hydrazones; D045283:Natriuretic Agents; D011724:Pyridazines; D011725:Pyridines; D013777:Tetrazoles; D014665:Vasodilator Agents; D014667:Vasopressins; D020097:Natriuretic Peptide, Brain; D000077464:Simendan; C120582:tezosentan